Symbicort Turbuhaler 30/60 Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- Registration Number
- NCT01232348
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3643
Inclusion Criteria
- Patients treated with Symbicort for the first time due to bronchial asthma
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Adverse Events Range of 12 weeks
- Secondary Outcome Measures
Name Time Method The level of asthma control Range of 12 weeks The level of patient satisfaction with Symbicort Range of 12 weeks
Trial Locations
- Locations (1)
Research Site
🇯🇵Yamanashi, Japan